Welcome to BOTOX Patient Navigator

QULIPTA INDICATION¹

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION¹

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS

Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

DRUG INTERACTIONS

Dose modifications are recommended when using the following:

• Episodic migraine: Strong CYP3A4 inhibitors; CYP3A4 inducers; or OATP inhibitors
• Chronic migraine: OATP inhibitors

In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.

USE IN SPECIFIC POPULATIONS

Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.

Avoid use in patients with severe hepatic impairment.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

Please see full Prescribing Information for QULIPTA.

UBRELVY INDICATION²

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION²

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

• Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
• Dose modifications are recommended when using the following:

- Moderate or weak CYP3A4 inhibitors and inducers

- BCRP and/or P-gp only inhibitors

DOSAGE AND ADMINISTRATION

• The recommended dose is 50 mg or 100 mg taken orally, as needed.
• If needed, a second dose may be administered at least 2 hours after the initial dose.
• The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
• Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
• Avoid use in patients with end-stage renal disease.

Please see full Prescribing Information for UBRELVY.

References:
1. QULIPTA [package insert]. North Chicago, IL: AbbVie Inc.
2. UBRELVY [package insert]. North Chicago, IL: AbbVie Inc.